Clinical Trial Update: The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. [Phase 3]

View source ↗

Summary

Phase 3 randomized trial assessing whether adjuvant lenvatinib reduces recurrence risk after hepatectomy in hepatocellular carcinoma with microvascular invasion…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: UNKNOWN